ArticleClinical transplantation2026
Development of a Donor-Based Predictive Model for Pancreas Non-Utilization Among Deceased Donor Transplants in the US.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPancreas non-utilization affects 25%-30% of deceased donor offers in the US. The European-derived Pre-Procurement Pancreas Suitability Score (P-PASS) has performed inconsistently, is not validated in North America, and requires less accessible inputs, highlighting need for a robust prediction tool for non-utilization.
methodsWe developed a predictive model for pancreas non-utilization using procured offers from the US SRTR (2003-2023). A multivariable logistic model used variables selected by causal diagram, LASSO, and univariable analyses. Model performance was evaluated using discrimination (AUC), calibration, and net reclassification improvement (NRI) versus a modified P-PASS. Internal validation used 1000 bootstrap resamples. Sensitivity analyses included recent-era offers, an all-comer cohort including non-procured offers, and excluding non-donor-related non-utilizations.
resultsAmong 30 757 pancreas offers, 26% were non-utilized. The model incorporated ten factors: older age, male sex, higher BMI, hypertension, gastrointestinal disease, smoking, donation after cardiac death, stroke as cause of death, elevated terminal creatinine, and abnormal lipase. This model achieved moderate discrimination (AUC 0.699; optimism-corrected 0.698), accurate calibration, Brier score 0.090, and 9.2% NRI. Sensitivity analyses confirmed robust performance, including AUC 0.8 among all-comer offers.
conclusionsThis model provides a practical, data-driven tool that improves identification of high-risk pancreata and may support more consistent, efficient utilization decisions. By demonstrating modifiable center-level variation and outperforming P-PASS in its first North American external validation, our findings offer a strong evidence base for targeted quality-improvement and policy initiatives to enhance pancreas transplant activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.